Back to top
more

Aquestive Therapeutics (AQST)

(Delayed Data from NSDQ)

$5.52 USD

5.52
1,317,489

+0.03 (0.55%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $5.52 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of 51.85% and 6.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 72.73% and 59.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 16th

ALB, AAL and AQST have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2024.

New Strong Sell Stocks for July 11th

AQST, CENTA and RAMP have been added to the Zacks Rank #5 (Strong Sell) List on July 11, 2024.

Kinjel Shah headshot

5 Small Drug Stocks to Buy From a Recovering Industry

Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics

The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -88.89% and 1.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?

Verrica Pharmaceuticals (VRCA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note

Aquestive Therapeutics (AQST) concluded the recent trading session at $4.14, signifying a +0.24% move from its prior day's close.

Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know

In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $4.38, denoting no change from the preceding trading day.

Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals

Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.

Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?

Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -50% and 12.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Bulls Look Optimistic About Aquestive Therapeutics (AQST): Should You Buy?

According to the average brokerage recommendation (ABR), one should invest in Aquestive Therapeutics (AQST). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Aquestive Therapeutics (AQST) Outperforms Broader Market: What You Need to Know

Aquestive Therapeutics (AQST) closed the most recent trading day at $3.67, moving +0.55% from the previous trading session.

Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect

Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.

Aquestive Therapeutics (AQST) Registers a Bigger Fall Than the Market: Important Facts to Note

In the latest trading session, Aquestive Therapeutics (AQST) closed at $2.65, marking a -1.67% move from the previous day.

Aquestive Therapeutics (AQST) Rises Higher Than Market: Key Facts

The latest trading day saw Aquestive Therapeutics (AQST) settling at $2.68, representing a +1.13% change from its previous close.

Why Aquestive Therapeutics (AQST) Outpaced the Stock Market Today

Aquestive Therapeutics (AQST) closed at $2.68 in the latest trading session, marking a +1.52% move from the prior day.

Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why

Aquestive Therapeutics (AQST) reachead $2.63 at the closing of the latest trading day, reflecting a -1.5% change compared to its last close.

Aquestive Therapeutics (AQST) Increases Despite Market Slip: Here's What You Need to Know

Aquestive Therapeutics (AQST) reachead $2.39 at the closing of the latest trading day, reflecting a +0.84% change compared to its last close.

Aquestive Therapeutics (AQST) Stock Slides as Market Rises: Facts to Know Before You Trade

The latest trading day saw Aquestive Therapeutics (AQST) settling at $2.50, representing a -0.4% change from its previous close.